---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007698"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T09:41:19.877392+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Telomir stabilizes Silver(II) in biological form, enabling antimicrobial and wound care applications

## Summary
- Telomir-1 successfully captured and stabilized both Silver(I) and Silver(II) (Ag²⁺) in a biologically compatible form.
- Silver(II) has superior antimicrobial properties but was previously too unstable for medical use.
- The breakthrough opens opportunities in advanced wound care, infection-resistant coatings, and antimicrobial treatments.
- Company will continue preclinical research and explore regulatory pathways for Silver(II)-complexed Telomir-1.
- No financial guidance or revenue impact provided; stage remains preclinical.

## SEC filing metadata
- accession: 0001493152-25-007698
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225007698/0001493152-25-007698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225007698/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007698
- JSON: https://secwatch.observer/filing/0001493152-25-007698.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.